Lotus Pharmaceutical Co., Ltd. (1795.TW)
| Previous Close | 300.00 |
| Open | 300.00 |
| Bid | 285.00 x N/A |
| Ask | 285.50 x N/A |
| Day's Range | 283.50 - 302.00 |
| 52 Week Range | 205.00 - 349.50 |
| Volume | |
| Avg. Volume | 6,846,111 |
| Market Cap | 75.506B |
| Beta (5Y Monthly) | 0.52 |
| PE Ratio (TTM) | 18.23 |
| EPS (TTM) | 15.66 |
| Earnings Date | Apr 30, 2024 |
| Forward Dividend & Yield | 3.46 (1.15%) |
| Ex-Dividend Date | Jul 05, 2023 |
| 1y Target Est | 433.33 |
- Business Wire
Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY® in Multiple Markets Across Asia
BOSTON & TAIPEI, Taiwan, August 10, 2023--Corium, LLC ("Corium"), a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Lotus Pharmaceutical (1795:TT; "Lotus"), a multinational pharmaceutical company, announced that the companies have entered into an exclusive Collaboration and License Agreement for ADLARITY® (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in ten markets across Asia.
GlobeNewswireAmarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
Collaboration Broadens Reach of VAZKEPA to Additional Ten Countries Leveraging Lotus’ Established Commercial and Marketing Expertise in the RegionDUBLIN, Ireland and BRIDGEWATER, N.J. and NANTOU, Taiwan, July 31, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) and Lotus Pharmaceuticals (1795:TT; “Lotus”) today announced that the two companies have entered into a long-term exclusive partnership to distribute and commercialize VAZKEPA® (icosapent ethyl) across 10 countries, including
GlobeNewswireNRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101
NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen to collaborate on the further development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD) for global marketsLotus Pharmaceuticals will acquire worldwide rights for NRX-101 for S-TRBD and will be responsible for commercialization of NRX-101 in markets outside the US through Lotus’s direct presence in certain Asian markets or through their export division, which currently has partnerships in numer
